Home > Mini Cooper > Acomplia aventis rimonabant sanofi

Acomplia aventis rimonabant sanofi

He’s not alone in acomplia aventis rimonabant sanofi his enthusiasm. Those whose pills were switched regained much of their lost acomplia aventis rimonabant sanofi weight. The new data comes from Sanofi-Aventis’ first non-obesity trial with Acomplia. The results of the six month trial, dubbed Serenade, were presented at the International Diabetes acomplia aventis rimonabant sanofi federation World Diabetes Congress in Cape Town, South Africa. The timing is auspicious. "We should be encouraged that the drug appears safe at 2 years and effective" at maintaining weight loss. He’s on the advisory board of Sanofi-Aventis. In the study’s second year, half of each group that had been receiving rimonabant was unknowingly switched to placebos. Robert Anthenelli of the University of Cincinnati College of Medicine and the Cincinnati Veterans Affairs Medical Center. It is the first of a new generation of drugs set to hit the market in the next few years that could transform obesity, still a small acomplia aventis rimonabant sanofi market, into a gold mine for the pharmaceutical industry. The trial showed that HbAIc blood acomplia aventis rimonabant sanofi sugar levels in patients on a once-daily 20 mg. George Kunos of the institute. As for health-threatening side effects of the drug, "there don’t seem to be any red flags coming up over 2 years,’ said Pi-Sunyer. The French company named its U. In America, obesity and its complications are estimated to cost the country $70bn (pounds acomplia aventis rimonabant sanofi 37bn) annually, according to Scrip Reports. Sanofi-Aventis ranks as the world’s third-largest drug company, trailing Pfizer and GlaxoSmithKline, and is tied as acomplia aventis rimonabant sanofi the seventh-largest in the U. , where it has 4. 3 acomplia aventis rimonabant sanofi percent market share and $9. 7 billion in sales, according to IMS Health data. Nevertheless, he remains circumspect acomplia aventis rimonabant sanofi about the safety of the drug until there are data over longer periods and in groups with different characteristics. Stock: Sanofi-Aventis Price (June 10, 2005) $86. 43 Price Target $94. 48 52-Week Range $89. 63 Industry view: attractive First analysis of the RIO acomplia aventis rimonabant sanofi diabetes data from Acomplia (rimonabant) medicated patients was presented at American Diabetes Association scientific sessions, June 12. Alimera Sciences, an ophthalmic pharmaceutical company, said the FDA approved an Rx-to-OTC switch new acomplia aventis rimonabant sanofi drug application for its ophthalmic solution Alaway (ketotifen fumarate ophthalmic solution 0. That burnished the drug’s reputation after two studies in March, which suggested it could fight both obesity and smoking, two of humanity’s biggest killers.